You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories Test Catalog
HERPES SIMPLEX VIRUS 1 AND 2 (IGG) TYPE-SPECIFIC ANTIBODIES |
||
Geisinger Epic Procedure Code: LAB2456
Geisinger Epic ID: 15000
|
||
SPECIMEN COLLECTION |
||
Specimen type: |
Serum | |
Preferred collection container: |
||
Alternate Collection Container: |
6 mL red-top (plain, non-serum separator) tube
|
|
Specimen required: |
1 mL serum; minimum 0.5 mL | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Allow to clot. Centrifuge and aliquot. | |
Transport temperature: |
Refrigerated. | |
Specimen stability: |
Room temperature: 7 days. Refrigerated: 14 days. Frozen: 30 days. | |
Rejection criteria: |
Gross hemolysis • Grossly lipemic • Plasma | |
TEST DETAILS |
||
CPT code(s): |
86695, 86696 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
HSV I IgG, HSV II IgG antibody detection. | |
Methodology: |
Immunoassay |
|
Synonyms: |
HSV I & II IgG, HERPG Type-specific Herpes IgG Herpes simplex virus types I & II IgG Quest test code 6447
|
|
Clinical significance: |
Herpes Simplex Virus (HSV) is responsible for several clinically significant human viral diseases, with severity ranging from inapparent to fatal. Clinical manifestations include genital tract infections, neonatal herpes, meningoencephalitis, keratoconjunctivitis, and gingivostomatitis. There are two HSV serotypes that are closely related antigenically. HSV Type 2 is more commonly associated with genital tract and neonatal infections, while HSV Type 1 is more commonly associated with infections of non-genital sites. Specific typing is not usually required for diagnosis or treatment. The mean time to seroconversion using the type specific assay is 25 days. The performance of this assay has not been established for use in a pediatric population, for neonatal screening, or for testing of immunocompromised patients. | |